PEGylated human adrenomedullin - Himuka AM Pharma
Alternative Names: adrenomedullin; HM-101-Himuka AM Pharma; HM-201; HM101Latest Information Update: 26 Apr 2023
At a glance
- Originator Himuka AM Pharma
- Class Anti-inflammatories; Antivirals; Peptides; Polyethylene glycols; Vasodilators
- Mechanism of Action Adrenomedullin replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II COVID-19 pneumonia
- Phase I Crohn's disease; Ulcerative colitis
Most Recent Events
- 19 Dec 2022 Syneos Health completes a phase I trial in Crohn's Disease in Australia (IV) (NCT05088369)
- 11 Nov 2021 Phase-I clinical trials in Crohn's disease in Australia (IV) (NCT05088369)
- 11 Nov 2021 Phase-I clinical trials in Ulcerative colitis in Australia (IV) (NCT05088369)